Pavel Mazanek
Overview
Explore the profile of Pavel Mazanek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyr M, Mudry P, Polaskova K, Dubska L, Demlova R, Kubatova J, et al.
Int J Cancer
. 2024 Jul;
155(8):1443-1454.
PMID: 38958237
A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here,...
2.
Mazankova D, Barkova V, Mazanek P
Ceska Slov Farm
. 2022 Sep;
71(3):91-97.
PMID: 36058637
Metronomic therapy is a therapeutic method in selected oncological diseases, using long-term administration of low doses of drugs with direct or indirect antitumor effect. In addition, to direct cytotoxic eradication...
3.
Polaskova K, Merta T, Martincekova A, Zapletalova D, Kyr M, Mazanek P, et al.
Front Oncol
. 2020 Mar;
9:1531.
PMID: 32117783
Summary: The main aim of this study is to analyze three relapsed Burkitt lymphoma patients using a comprehensive molecular profiling, in order to explain their different outcomes and to propose...
4.
Veselska R, Jezova M, Kyr M, Mazanek P, Chlapek P, Dobrotkova V, et al.
Front Oncol
. 2019 Dec;
9:1221.
PMID: 31803613
The survival rate for patients with high-risk neuroblastomas remains poor despite new improvements in available therapeutic modalities. A detailed understanding of the mechanisms underlying clinical responses to multimodal treatment is...
5.
Fedorova L, Mudry P, Pilatova K, Selingerova I, Merhautova J, rehak Z, et al.
Front Oncol
. 2019 Dec;
9:1169.
PMID: 31799177
Monocyte-derived dendritic cell (DC)-based vaccines loaded with tumor self-antigens represent a novel approach in anticancer therapy. We evaluated DC-based anticancer immunotherapy (ITx) in an academic Phase I/II clinical trial for...
6.
Hlavackova E, Pilatova K, Cerna D, Selingerova I, Mudry P, Mazanek P, et al.
Front Oncol
. 2019 Nov;
9:1034.
PMID: 31709173
Despite efforts to develop novel treatment strategies, refractory and relapsing sarcoma, and high-risk neuroblastoma continue to have poor prognoses and limited overall survival. Monocyte-derived dendritic cell (DC)-based anti-cancer immunotherapy represents...
7.
Dobrotkova V, Chlapek P, Jezova M, Adamkova K, Mazanek P, Sterba J, et al.
PLoS One
. 2019 Jun;
14(6):e0218269.
PMID: 31188873
Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop...
8.
Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, et al.
JCI Insight
. 2018 Dec;
3(23).
PMID: 30518699
In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of noninvasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743...
9.
Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R
BMC Cancer
. 2018 Nov;
18(1):1059.
PMID: 30384831
For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have...
10.
Chlapek P, Slavikova V, Mazanek P, Sterba J, Veselska R
Int J Mol Sci
. 2018 Jan;
19(1).
PMID: 29301374
Retinoids represent a popular group of differentiation inducers that are successfully used in oncology for treatment of acute promyelocytic leukemia in adults and of neuroblastoma in children. The therapeutic potential...